InflaRx NV
IFRX0.895USD
+0.035+4.13%
Horário de mercado （ET）Cotações atrasadas em 15 min
56.70MValor de mercado
PerdaP/L TTM
Mais detalhes de InflaRx NV Empresa
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Informações da empresa
Código da empresaIFRX
Nome da EmpresaInflaRx NV
Data de listagemNov 08, 2017
CEOProf. Niels C. Riedemann, M.D., Ph.D
Número de funcionários74
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 08
EndereçoWinzerlaer Str. 2
CidadeJENA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísGermany
Código postal07745
Telefone493641508180
Sitehttps://www.inflarx.de/
Código da empresaIFRX
Data de listagemNov 08, 2017
CEOProf. Niels C. Riedemann, M.D., Ph.D
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Detalhamento da receita
Moeda: EURAtualizado em: qua, 5 de mar
Moeda: EURAtualizado em: qua, 5 de mar
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoEUR
Nome
Receita
Proporção
Germany
0.00
0.00%
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 29 de jul
Atualizado em: ter, 29 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Suvretta Capital Management, LLC
9.66%
683 Capital Management LLC
3.91%
Guo (Renfeng M.D.)
2.62%
Eversept Partners, LP
2.50%
Morgan Stanley & Co. LLC
1.88%
Other
79.43%
Investidores
Investidores
Proporção
Suvretta Capital Management, LLC
9.66%
683 Capital Management LLC
3.91%
Guo (Renfeng M.D.)
2.62%
Eversept Partners, LP
2.50%
Morgan Stanley & Co. LLC
1.88%
Other
79.43%
Tipos de investidores
Investidores
Proporção
Hedge Fund
20.49%
Individual Investor
6.44%
Investment Advisor
3.05%
Research Firm
2.34%
Investment Advisor/Hedge Fund
0.39%
Venture Capital
0.06%
Other
67.23%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
85
22.00M
32.77%
-470.85K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
2023Q2
95
25.76M
47.58%
+2.86M
2023Q1
90
10.99M
24.57%
-8.39M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Suvretta Capital Management, LLC
6.48M
9.66%
+750.00K
+13.08%
Mar 31, 2025
683 Capital Management LLC
2.63M
3.91%
+555.00K
+26.81%
Mar 31, 2025
Guo (Renfeng M.D.)
1.76M
2.62%
--
--
Dec 31, 2024
Eversept Partners, LP
1.68M
2.5%
+1.18M
+240.33%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.26M
1.88%
-776.51K
-38.11%
Mar 31, 2025
SilverArc Capital Management, LLC
1.16M
1.73%
+1.16M
--
Mar 31, 2025
Riedemann (Niels C. M.D.)
1.07M
1.59%
--
--
Dec 31, 2024
Mark (Christian Kubler)
960.01K
1.43%
--
--
Dec 31, 2024
Woodline Partners LP
750.98K
1.12%
+750.98K
--
Mar 31, 2025
StemPoint Capital LP
725.02K
1.08%
+725.02K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ALPS Medical Breakthroughs ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ALPS Medical Breakthroughs ETF
Proporção0%
Invesco Raymond James SB-1 Equity ETF
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
